UUÂãÁÄÖ±²¥

Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information.

Combating antibiotic resistance through ligand- and structure-based virtual screening

3 December 2024 14:00-14:40


Introduction
Date: Tuesday 3rd December 2024
Time: 2pm GMT / 3pm CET / 9am ET / 7am PT
Duration: 35 minutes 
Format: Webinar

Physics-based virtual screening has substantially enhanced the drug discovery process by enabling precise predictions of ligand-receptor interactions, thereby reducing the computational cost and time associated with identifying high-affinity drug candidates. As a result, it has become a routine and indispensable tool in the drug designer's toolbox, offering a reliable method for optimizing lead compounds and accelerating the development of new therapeutics.

In this webinar, we will showcase how Cresset’s advanced virtual screening technologies were harnessed to identify inhibitors on an emerging antibacterial therapeutic target. The LasR transcriptional activator is part of the Quorum Sensing (QS) system. Inhibiting QS stunts bacterial proliferation and nullifies bacterial communication; thus, the aim of this work was to identify novel inhibitors as antibiotics to help combat antibiotic resistance for treatments of bacterial infections.

The virtual screening workflow deployed in this work leverages Flareâ„¢ to screen and rank compounds from open-source databases using 3D field-based virtual screening, docking, Electrostatic Complementarity and clustering in a holistic data driven approach to identify interesting leads.

Register here: https://www.cresset-group.com/about/events/combating-antibiotic-resistance/

Useful links

Contact information
Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*